Skip to main content

Table 3 SABA Prescriptions in the past 12 months for the SABINA III Gulf cluster cohort

From: Over-prescription of short-acting β2-agonists and asthma management in the Gulf region: a multicountry observational study

 

All

(N = 301)

Primary care physicians (n = 135)

Respiratory specialists (n = 162)

Mild asthma (n = 32)

Moderate-to-severe asthma

(n = 103)

All

(n = 135)

Mild asthma (n = 13)

Moderate-to-severe asthma

(n = 149)

All

(n = 162)

Prescription of SABA monotherapy, n (%)

 No

287 (95.3)

20 (62.5)

103 (100)

123 (91.1)

12 (92.3)

149 (100)

161 (99.4)

 Yes

14 (4.7)

12 (37.5)

0 (0)

12 (8.9)

1 (7.7)

0 (0)

1 (0.6)

SABA canisters or inhalers prescribed in the past 12 months

  Mean (SD)

8.9 (12.9)

10.2 (13.5)

NA

10.2 (13.5)

1.0 (NA)

NA

1.0 (NA)

  Median (min, max)

2.5 (1.0, 42.0)

3.0 (1.0, 42.0)

NA

3.0 (1.0, 42.0)

1.0 (1.0, 1.0)

NA

1.0 (1.0, 1.0)

SABA canisters or inhalers prescribed in the past 12 months by groups, n (%)

  0–2

7 (50)

5 (41.7)

NA

5 (41.7)

1 (100)

NA

1 (100)

  3–5

3 (21.4)

3 (25)

NA

3 (25)

0 (0)

NA

0 (0)

  6–9

0 (0)

0 (0)

NA

0 (0)

0 (0)

NA

0 (0)

  10–12

1 (7.1)

1 (8.3)

NA

1 (8.3)

0 (0)

NA

0 (0)

   ≥ 13

3 (21.4)

3 (25)

NA

3 (25)

0 (0)

NA

0 (0)

Prescription of SABA in addition to maintenance therapy/SABA add-on therapy, n (%)

 No

93 (30.9)

21 (65.6)

38 (36.9)

59 (43.7)

9 (69.2)

23 (15.4)

32 (19.8)

 Yes

208 (69.1)

11 (34.4)

65 (63.1)

76 (56.3)

4 (30.8)

126 (84.6)

130 (80.2)

SABA canisters or inhalers prescribed in the past 12 months

  Mean (SD)

8.0 (10.9)

7.6 (4.6)

10.6 (18.5)

10.2 (17.2)

7.8 (4.3)

6.8 (4.0)

6.8 (4.0)

  Median (min, max)

6.0 (1.0, 110.0)

9.0 (2.0, 12.0)

5.0 (1.0, 110.0)

5.0 (1.0, 110.0)

7.5 (4.0, 12.0)

6.0 (1.0, 24.0)

6.0 (1.0, 24.0)

SABA canisters or inhalers prescribed in the past 12 months by groups, n (%)

  0–2

39 (18.8)

3 (27.3)

20 (30.8)

23 (30.3)

0 (0)

15 (11.9)

15 (11.5)

  3–5

54 (26)

2 (18.2)

15 (23.1)

17 (22.4)

2 (50)

35 (27.8)

37 (28.5)

  6–9

61 (29.3)

1 (9.1)

13 (20)

14 (18.4)

0 (0)

46 (36.5)

46 (35.4)

  10–12

37 (17.8)

5 (45.5)

8 (12.3)

13 (17.1)

2 (50)

22 (17.5)

24 (18.5)

   ≥ 13

17 (8.2)

0 (0)

9 (13.8)

9 (11.8)

0 (0)

8 (6.3)

8 (6.2)

  1. Prescriber type was not recorded for two patients each in mild asthma and moderate-to-severe asthma group
  2. Abbreviations: max maximum, min minimum, NA not available, SABA short-acting β2-agonist, SABINA SABA use IN Asthma, SD standard deviation